Outpatient Program Helps CHIPSA Expand Services To More Patients

When we introduced our outpatient program we were able to positively impact the expense of getting treated by CHIPSA.  In many cases, the cost of care here at CHIPSA was reduces as much as 90%.

We've been on the forefront of integrative medicine and immunotherapy for 38 years. The treatments at CHIPSA have stood the test of time. Some treatments have been administered for over 20 years at CHIPSA and are just now getting FDA approval with only small changes to the immunotherapies.

Sadly, many patients cannot afford to go to Mexico and stay at the hospital for 3 weeks.

“Every month we have to turn away over 300 patients due to them not having enough money for our treatments. This sad fact has driven us to figure out a way to put together a powerful program at a much lower cost.” – Dr. Pablo Fok MD, CHIPSA General Surgeon

To accomplish this goal, CHIPSA has built a fully renovated Outpatient Treatment Room (OTR) at the hospital and partnered with hotels and realtors to house people during their stay.

In the United States however, outpatient and appendant treatments have an out of pocket cost to patients of $140,000- $300,000. This is simply out of reach for many patients seeking the potentially life saving therapy.

CHIPSA Hospital Recruits 3 World Class Cancer Scientists!

CHIPSA Hospital Recruits 3 World Class Cancer Scientists! We are happy to announce the inaugural members of our scientific advisory board. Dr. Franco Marincola, Dr. Philip Kim, Dr. Vijay Mahant.

Dr. Francesco Marincola - MD

Dr. Marincola is considered one of the worlds leading tumor Immunologists. He was the Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institute of Health in Bethesda. He was founder and serves as Editor-in-Chief, Journal of Translational Medicine and ASHI Quarterly, senior editor for the Journal of the American Society for Histocompatibility and Immunogenetics, and editor for a variety of academic journals, including Immunotherapy, Journal of Immunotherapy, Journal of Immunology, Tumori, Clinical Cancer Research, Biological Therapy, and Cancer Immunology and Immunotherapy. He is also a founding member of the Society for Immunotherapy of Cancer.

Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. In particular, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics laboratory is recognized nationally and internationally for the cutting edge technologies applied for the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.

Dr. Vijay Mahant, MS, PhD.

Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate from MD Anderson in Houston TX.  Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics.  He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in Research and Development including Auto Genomics, Medi-Lite and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer. 

Dr. Mahant’s work can be seen all over the world in leading cancer institutions using his cutting edge genetic and diagnostic equipment. He has been on the forefront of the liquid biopsy and circulating tumor cell movement. His passion is to find ways to match tumors with specific drugs that might be off label and to create even better early detection diagnostic tests.

Dr. Phillip S. Kim PhD.

Dr. Kim was awarded the human genetics fellowship by the National Institute of Health (NIH) at the  Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of ‘Geno-dynamics’ system to investigate gene function.

At Prometheus he led oncology and gastroenterology research teams to develop technologies, platforms and services for personalized/ targeted diagnostic applications with prognostic, predictive and monitoring utilities for oncology and autoimmune diseases. 

His work included  managing planning & execution of technical projects, clinical trials, science and technology communications, research collaborations & KOL (Key Opinion Leader) relationships, and publications.

He is the inventor of the immune pod which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific for individual’s tumor for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using ‘Immuno-Pod’ maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous ‘synthetic met’ ex vivo seamlessly integrated for each patient.

Dr. Kim’s valuable insight at CHIPSA will help guide decisions for precision medicine and specific immune response for all patients.

How CHIPSA Is A Leader In Advanced Immunotherapy

CHIPSA has also added three other treatments unavailable in the United States to go along with the IPT.  These therapies build on the 38 years of innovative immunotherapy at CHIPSA. Well before the United States recognized immunotherapy as a treatment, physicians at CHIPSA were using it with great success.

Treatment #1 – Insulin Potentiated Therapy (IPT)

Insulin Potentiation Therapy (IPT) is a revolutionary and innovative approach to treating cancer. Also known as low dose chemotherapy, IPT is believed to have far lower rate of some of the side effects associated with conventional cancer treatment such as nausea, radical hair loss, liver damage, immune suppression and DNA destruction.

The cornerstone of IPT as a cancer treatment lies in use of insulin.  In the human body, insulin is the mechanism for the delivery of glucose from the bloodstream, across cell membranes, and into the cells. Ironically, cancer cells have up to 20 times more insulin receptors than normal cells because cancer requires glucose (sugar) for its energy production.

How Sugar Is Used To Kill Cancer

When insulin is released into the bloodstream for instance, after consuming a meal, the insulin attaches to receptors on the cell and allow nutrients like glucose(sugar) to permeate the cell membrane.

Because cancer cells have far more of these insulin receptors, they push out the body’s normal cells and go after insulin so they can get that glucose they crave. IPT uses cancer’s appetite for sugar to its advantage, allowing the low dose chemo to be delivered directly to the cell…kind of like a trojan horse.

It is at this crucial point that a patient will be administered an extremely low dose of chemotherapy (about 1/10th the amount of a conventional dose) mixed with glucose. The cancer cells so desperate to get the sugar they need are believed to take in almost all of the cancer killing chemo. This is why there are far fewer side effects experienced with IPT.

Treatment #2 – Intravenous Vitamin CK3

The effects of IPT are thought be enhanced with the addition of  Intravenous Vitamin C+K3. CHIPSA hospital is leading the way with this treatment and making it accessible to patients in financial constraints.

For example, the amount of Intravenous K3 used in the therapy, alone, in the United states would cost a patient close to $100,000.

The ratio is 100:1, which means for every gram of Vitamin C there is 10 mg of K3 given.

Vitamin C+K3 is a largely studied substance that received an FDA trial in 2006.

The results were promising with 15 of the 16 patients showing a response. Unfortunately, the trial was not allowed to move forward for unknown reasons.

CHIPSA begins C+K3 administration with the same dose used in the FDA trial and slowly works up under the watchful eye of CHIPSA physicians. Around 80% of patients will experience pain in their tumor site during the 2 hour intravenous drip.

What The Researchers Discovered About This Treatment

Researchers combined vitamins C and K3 at ratio of 100:1 after in vivo administration in tumor-bearing mice produced and found the following:

Cancer growth inhibition in transplantable liver tumor (TLT)-bearing mice with an increase in life span (ILS) of 45.8%. Neither vitamin C nor vitamin K3 administered alone has any significant effect on the life span of TLT-bearing animals. It must be in the 100:1 ratio.

Selective potentiation of tumor chemotherapy. For instance, while cyclophosphamide alone, at a single sub-therapeutic dose of 80 mg kg1 body weight increased the life span by 23%, its association with CK3, increased the life span by 59.5%

Sensitization of tumors resistant to some drugs. The pretreatment of TLT-bearing mice with CK3 before injection of Oncovin increases the life span by 97.3%.

Additionally examinations of CK3-treated mice did not indicate any sign of toxicity in normal organ and tissues.

How CK3 Is Killing Cancer

What appears to be happening is that the introduction of CK3 to cancer cells, forms cuts or schisms in the cell membrane, which allows the cytoplasm to leak out. The researchers called this autoschizis. The cell shrinks in size until about only 1/3 its original size and only the nucleus and organelles remain surrounded by a tiny ribbon of cytoplasm. If apoptosis is a quiet cell suicide in which the cell curls up and dies, autoschizis (necrosis) is a bit more violent; the cell slashes itself open violently spilling out its insides.

Studies have looked at autoschizis in experiments with:

Ovarian cancer cells

Liver tumors Bladder tumors

Oral squamous cell and salivary gland tumors,

And Leukemia.

Pretreatment with this vitamin C/K combination also potentiates the effect of chemotherapy and radiation. It also appears to be nontoxic, leaving normal cells unaffected.

Enter Oxygen Therapy

CHIPSA has added 3 hyperbaric oxygen sessions a week to this package. Hyperbaric oxygen is FDA approved for many ailments in the United States but for “off label” uses like being an adjunct cancer treatment is not covered under U.S. insurance.

This makes hyperbaric oxygen sessions between $1,000-$2,000 per session in a hospital setting. Some small clinics in the United States offer treatments for as low as $300 per session but the depth at which the tank takes you too is many times not as strong as a hospital grade chamber. Hyperbaric oxygen is approved by the Cofe Pris in Mexico as an adjunct cancer treatment thus making it readily available. CHIPSA recently installed a $500,000 chamber that can hold up to 8 people.

Treatment #3 – Coley’s Therapy

Hailed by some as “The World’s Most Powerful Cancer Treatment”, Dr. William  Coley developed this treatment while he was surgeon at Memorial Hospital in 1891.

He began his search for other cancer treatment when one of his sarcoma patients, Bessie Dashiell died after Dr. Coley had followed strict protocol of the time. He amputated her arm, expecting that to stop the cancer. Instead the cancer came back with a vengeance and Bessie died a very painful death.​

Devastated by what had transpired, Dr. Coley scoured Memorial hospital’s records searching for anybody that had survived sarcoma. At last he came across a “one” patient who had beat the cancer. Ironically this patient had contracted an Erysipelas infection, a type of Streptococcus bacteria. Dr. Coley traveled to Manhattan to meet this patient and to his surprise the patient was still alive and well, 7 years cancer free. In fact, the patient lived for 27 years more and died of a heart attack. At the time of death he was cancer free

Dr Coley surmised that if an accidental infection cured the cancer, that an intentional infection would produce similar results. He believed that the infection triggered an immune response that allowed the body attack the cancer itself.

How It Works

Coley’s Mixed Vaccine is comprised of a sterile(dead) mixture of gram-positive Streptococcus pyogenes and gram-negative Serratia marcescens bacteria. By introducing the killed bacteria into the body, Dr. Coley could mimic an immune response without the risk of infection.

Coley’s toxins also causes  a short term fever. This treatment is done twice a week along with the IPT to maximize the effects. The fever is thought to weaken cancer cells and the body’s reaction to the Coley’s fluid causes a dendritic cell and NK Killer cell storm. The idea is that while the IPT is killing cancer cells it’s also alerting the body of the existence of the cancer.

Beating Cancer As a Whole

Here at CHIPSA Hospital we utilize the treatments above as part of our integrative approach to treating cancer and autoimmune disease.

We are not in any way, shape or form, stating that we have a cure for cancer. It’s very common to see alternative practitioners making claims that one substance or “thing” is an all out cure.

Lara’s Of Results of IPT and CK3 in Just 5 Weeks

We know from our experience in treating cancer for 37 years , that cancer is very complex and always evolving. There is no 100% cure. What we do know, however, is that CHIPSA has had great success treating many patients that were sent home to “die” in their home country because conventional medicine failed them. We also know, that a 5 year, retrospective Melanoma case study done at our hospital showed a higher success rate treating Melanoma than any treatment available by the establishment.

And we do know that many times within a 3 week stay, we will see people’s tumor markers be cut in half or go away and large tumors disappear.

We feel that combining of our proven immune boosting protocols and our 37 years of research into immune function may allow for some groundbreaking cancer treatments and get us closer to an answer.

 How CHIPSA Reduces Treatment Cost By Almost 80%

 The cost of IV vitamin C+K3 and IPT alone would cost a patient approximately $140,000. Add hyperbaric oxygen and our antigenic peptide vaccine that’s unavailable in the United States at the total cost for treatment would be in excess of $155,000 for 3 weeks in the United States.

If you or someone you love would like more information on receiving the above treatments for 3 weeks at CHIPSA at over 80% off the price in the United States please click the button below and enter your information. We will be happy schedule you a free 30 minute appointment to talk to one of our doctors to help you make an informed decision about your treatment.

Click Here To Speak With a Doctor For Free!

Got More Questions?

Get In Contact With CHIPSA Hospital Directly By Calling 1-(855) 338-2460 ​ To Speak With A Doctor For Free!